1[1]Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem,1999,274(19)∶13451-13455.
2[2]Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst,1996,88 (19)∶1383-1392.
3[3]Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer,1996,66(3)∶374-379.
4[5]Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor alpha: Phase Ⅰ and phase Ⅲ clinical trials. Pol Merkuriusz Lek,1997,2(12)∶396-399.
5[6]Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res,1998,18(5D)∶3937-3939.
6[7]Du Bois JS, Trehu EG, Mier JW, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol,1997,15(3)∶1052-1062.
7[8]Libutti SK, Barlett DL, Fraker DL, et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg,2000,191(5)∶519-530.
8[9]Nakamoto T, Inagawa H, Takagi K, et al. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res,2000,20(6A)∶4087-4096.
9[10]Fukushima T, Yamamoto M, Ikeda K, et al. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res,1998,18(5D)∶3965-3970.
10Eggermont AMM, Schreffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial[J]. Clin Oncol, 1996, 14:2653-2665.
2de Kock I, Mirhosseini M, Lau F, et al. Conversion of Kamofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools [ J ]. J Palliat Care,2013,29(3) :163.
3Tsang TS, Barnes ME, Hayes SN, et al. Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentcsis for management: Mayo Clinic experience, 1979-1998. [ J]. Chest, 1999, 116(2) :322-331.
